ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Colorectal Cancer

Colorectal Cancer

No difference in time to recurrence, recurrence-free survival, or overall survival were noted for patients with rectal cancer who underwent one of three different preoperative radiotherapy regimens.

Completing a course of preoperative radiotherapy prior to undergoing surgical resection for rectal cancer was associated with improved survival compared with patients who had an incomplete course of radiotherapy.

A study found that normal-weight women should be evaluated for metabolic health to reduce their risk for colorectal cancer.

Young and middle-aged patients diagnosed with colon cancer were more likely to receive postoperative chemotherapy compared with their older-age counterparts, according to the results from a recent cohort study.

Using immunohistochemistry to measure the expression of certain target enzymes—cox-2 and 15-prostaglandin dehydrogenase (15-PGDH)—in premalignant colorectal adenomas, researchers were able to get significant predictive and prognostic information in patients treated with the cox-2 inhibitor celecoxib for prevention of colorectal adenomas.

The addition of the BRAF inhibitor vemurafenib to irinotecan and cetuximab prolonged progression-free survival and resulted in a higher disease control rate than treatment with irinotecan and cetuximab alone in patients with BRAF-mutant metastatic colorectal cancer.

The immune checkpoint inhibitor nivolumab showed durable responses and disease control in a group of heavily pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer.

Pages

Subscribe to Colorectal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.